SEC Form 4 · accession 0001651625-26-000010
AC Immune SA · ACIU
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Martin Zuegel
Officer — Interim CEO · Director
Period of report
Jun 11, 2026
Accepted (ET)
Jun 15, 2026 · 6:50 am EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001651625
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common ShareF1,F2 | Jun 11, 2026 | A | 33,136 | $0.00 | A | 71,408 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Share Option (right to buy)F3 | $2.62 | Jun 11, 2026 | A | 77,778 | A | Jun 10, 2027 | Jun 10, 2036 | Common Share | 77,778 | 77,778 | D |
Explanation of responses
- F1On June 11, 2026, the Reporting Person received a restricted share unit grant of 33,136 units under the AC Immune SA 2016 Stock Option and Incentive Plan (SOIP).
- F2Comprised of 71,408 common shares underlying outstanding restricted share units.
- F3On June 11, 2026, the Reporting Person received share options with respect to 77,778 shares under the SOIP. The share options will fully vest on June 10, 2027.